## Luis Abel Quiñones

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/6208300/publications.pdf

Version: 2024-02-01

80 papers

1,379 citations

471061 17 h-index 34 g-index

96 all docs 96
docs citations

96 times ranked 1814 citing authors

#	Article	IF	Citations
1	Pulmonary Inflammatory Response in Lethal COVID-19 Reveals Potential Therapeutic Targets and Drugs in Phases III/IV Clinical Trials. Frontiers in Pharmacology, 2022, 13, 833174.	1.6	6
2	Novel Risk Associations between microRNA Polymorphisms and Gastric Cancer in a Chilean Population. International Journal of Molecular Sciences, 2022, 23, 467.	1.8	1
3	Pharmacogenomics: Challenges and Future Perspectives. , 2022, , 883-890.		О
4	Pharmacodynamic Polymorphisms. , 2022, , 853-861.		0
5	Pharmacogenomics: Genetic Polymorphisms. , 2022, , 890-899.		0
6	Pharmacogenomics: Basis and Milestones. , 2022, , 874-883.		o
7	Epithelial-Mesenchymal Transition and MicroRNAs in Colorectal Cancer Chemoresistance to FOLFOX. Pharmaceutics, 2021, 13, 75.	2.0	28
8	Pharmacokinetic Polymorphisms. , 2021, , 1-9.		1
9	Pharmacogenomics: Basis and Milestones. , 2021, , 1-10.		1
10	Pharmacogenomics: Genetic Polymorphisms. , 2021, , 1-10.		1
11	In silico Analyses of Immune System Protein Interactome Network, Single-Cell RNA Sequencing of Human Tissues, and Artificial Neural Networks Reveal Potential Therapeutic Targets for Drug Repurposing Against COVID-19. Frontiers in Pharmacology, 2021, 12, 598925.	1.6	16
12	Pharmacogenetics–Based Preliminary Algorithm to Predict the Incidence of Infection in Patients Receiving Cytotoxic Chemotherapy for Hematological Malignancies: A Discovery Cohort. Frontiers in Pharmacology, 2021, 12, 602676.	1.6	4
13	A New Insight for the Identification of Oncogenic Variants in Breast and Prostate Cancers in Diverse Human Populations, With a Focus on Latinos. Frontiers in Pharmacology, 2021, 12, 630658.	1.6	3
14	NOD1 rs2075820 (p.E266K) polymorphism is associated with gastric cancer among individuals infected with cagPAI-positive H. pylori. Biological Research, 2021, 54, 13.	1.5	5
15	Pharmacogenetic Associations Between Atazanavir/UGT1A1*28 and Efavirenz/rs3745274 (CYP2B6) Account for Specific Adverse Reactions in Chilean Patients Undergoing Antiretroviral Therapy. Frontiers in Pharmacology, 2021, 12, 660965.	1.6	5
16	Smartphone screen testing, a novel pre-diagnostic method to identify SARS-CoV-2 infectious individuals. ELife, 2021, 10, .	2.8	9
17	A case-control study of a combination of single nucleotide polymorphisms and clinical parameters to predict clinically relevant toxicity associated with fluoropyrimidine and platinum-based chemotherapy in gastric cancer. BMC Cancer, 2021, 21, 1030.	1.1	6
18	Análisis farmacogenético retrospectivo de una paciente pediátrica en tratamiento anticoagulante: caso clÃnico. Biomedica, 2021, 41, 403-408.	0.3	1

#	Article	IF	CITATIONS
19	Resolvin D1 reduces expression and secretion of cytokines and monocyte adhesion triggered by Angiotensin II, in rat cardiac fibroblasts. Biomedicine and Pharmacotherapy, 2021, 141, 111947.	2.5	3
20	Pharmacogenomics: Challenges and Future Perspectives. , 2021, , 1-8.		1
21	Frequency of CYP1A1*2A polymorphisms and deletion of the GSMT1 gene in a Peruvian mestizo population. Pharmacia, 2021, 68, 747-754.	0.4	5
22	Preliminary Pharmacogenomic-Based Predictive Models of Tamoxifen Response in Hormone-dependent Chilean Breast Cancer Patients. Frontiers in Pharmacology, 2021, 12, 661443.	1.6	3
23	Editorial: Pharmacogenetics and Pharmacogenomics in Latin America: Ethnic Variability, New Insights in Advances and Perspectives: A RELIVAF-CYTED Initiative. Frontiers in Pharmacology, 2021, 12, 833000.	1.6	3
24	Frequency of CYP2D6*3 and *4 and metabolizer phenotypes in three mestizo Peruvian populations. Pharmacia, 2021, 68, 891-898.	0.4	4
25	Effect of CYP3A4, CYP3A5, MDR1 and POR Genetic Polymorphisms in Immunosuppressive Treatment in Chilean Kidney Transplanted Patients. Frontiers in Pharmacology, 2021, 12, 674117.	1.6	8
26	Milk intake and IGF-1 rs6214 polymorphism as protective factors to obesity. International Journal of Food Sciences and Nutrition, 2020, 71, 388-393.	1.3	4
27	Pharmacogenomics, biomarker network, and allele frequencies in colorectal cancer. Pharmacogenomics Journal, 2020, 20, 136-158.	0.9	15
28	Current status of cancer pharmacogenomics. , 2020, , 233-243.		0
29	As3MT and GST Polymorphisms Influencing Arsenic Metabolism in Human Exposure to Drinking Groundwater. International Journal of Molecular Sciences, 2020, 21, 4832.	1.8	20
30	HLA-DRB1*07:01 and *08:02 Alleles Confer a Protective Effect Against ACPA-Positive Rheumatoid Arthritis in a Latin American Admixed Population. Biology, 2020, 9, 467.	1.3	5
31	Polymorphisms PSCA rs2294008, IL-4 rs2243250 and MUC1 rs4072037 are associated with gastric cancer in a high risk population. Molecular Biology Reports, 2020, 47, 9239-9243.	1.0	7
32	Latin American Genes: The Great Forgotten in Rheumatoid Arthritis. Journal of Personalized Medicine, 2020, 10, 196.	1.1	2
33	L-6 â^3572C>G and CARD8 304T>A Genetic Polymorphisms are Associated with the Absolute Neutrophil Count in Patients with Hematological Malignancies Under Chemotherapy: An Application of Multilevel Models to a Preliminary Pharmacogenetic Study. Pharmacogenomics and Personalized Medicine. 2020. Volume 13. 337-343.	0.4	2
34	Influence of BDNF Genetic Polymorphisms in the Pathophysiology of Aging-related Diseases. , 2020, 11, 1513.		14
35	Association analysis in a Latin American population revealed ethnic differences in rheumatoid arthritis-associated SNPs in Caucasian and Asian populations. Scientific Reports, 2020, 10, 7879.	1.6	6
36	Identification of Altered Genes in Gallbladder Cancer as Potential Driver Mutations for Diagnostic and Prognostic Purposes: A Computational Approach. Cancer Informatics, 2020, 19, 117693512092215.	0.9	13

#	Article	IF	Citations
37	A Pharmacogenetically Guided Acenocoumarol Dosing Algorithm for Chilean Patients: A Discovery Cohort Study. Frontiers in Pharmacology, 2020, 11, 325.	1.6	10
38	Functionally Significant Coumarin-Related Variant Alleles and Time to Therapeutic Range in Chilean Cardiovascular Patients. Clinical and Applied Thrombosis/Hemostasis, 2020, 26, 107602962090915.	0.7	5
39	Genetic polymorphisms as non-modifiable susceptibility factors to laryngeal cancer. Bioscience Reports, 2020, 40, .	1.1	8
40	Estudio de las variantes al $ ilde{A}$ ©licas CYP2C9*2 y CYP2C9*3 en muestras de poblaci $ ilde{A}$ 3n mestiza peruana. Biomedica, 2019, 39, 601-610.	0.3	8
41	Association Study Among Candidate Genetic Polymorphisms and Chemotherapy-Related Severe Toxicity in Testicular Cancer Patients. Frontiers in Pharmacology, 2019, 10, 206.	1.6	8
42	Anticoagulation Management With Coumarinic Drugs in Chilean Patients. Clinical and Applied Thrombosis/Hemostasis, 2019, 25, 107602961983434.	0.7	3
43	High prevalence of clarithromycin resistance and effect on Helicobacter pylori eradication in a population from Santiago, Chile: cohort study and meta-analysis. Scientific Reports, 2019, 9, 20070.	1.6	25
44	The role of phase I and II genetic polymorphisms, smoking, alcohol and cancer family history, in the risk of developing testicular cancer. Pharmacogenetics and Genomics, 2019, 29, 159-166.	0.7	9
45	Relationship Between Pharmacokinetics and Pharmacogenomics and Its Impact on Drug Choice and Dose Regimens., 2018,, 169-202.		4
46	Arsenic exposure, profiles of urinary arsenic species, and polymorphism effects of glutathione-s-transferase and metallothioneins. Chemosphere, 2018, 212, 927-936.	4.2	19
47	FarmacogenÃ <sup>3</sup> mica como herramienta fundamental para la medicina personalizada: aplicaciones en la práctica clÃnica. Revista Medica De Chile, 2017, 145, 483-500.	0.1	22
48	State of Art of Cancer Pharmacogenomics in Latin American Populations. International Journal of Molecular Sciences, 2017, 18, 639.	1.8	25
49	Abstract 5031: Distribution of single nucleotide polymorphisms related to paclitaxel and carboplatin toxicity in ovarian cancer patients. , 2017, , .		0
50	Genetic Polymorphisms Associated to Folate Transport as Predictors of Increased Risk for Acute Lymphoblastic Leukemia in Mexican Children. Frontiers in Pharmacology, 2016, 7, 238.	1.6	6
51	Reply to the commentary: Estimating genotype and allele frequencies of the CYP2D6 gene. Pharmacological Research, 2016, 110, 241.	3.1	0
52	Preclinical Evaluation of the <i>Enceliacanescens Lam</i> Extract: Medicinal Properties useful for Cancer Treatment. Journal of Natural Remedies, 2016, 15, 113.	0.1	0
53	Prevalence of seven cardiovascular-related genetic polymorphisms in a Chilean mestizo healthy population. Acta Cardiologica, 2015, 70, 528-535.	0.3	2
54	Editorial: Improving cancer chemotherapy through pharmacogenomics: a research topic. Frontiers in Genetics, 2015, 6, 195.	1.1	1

#	Article	IF	CITATIONS
55	Characterization of the CYP2D6 drug metabolizing phenotypes of the Chilean mestizo population through polymorphism analyses. Pharmacological Research, 2015, 101, 124-129.	3.1	21
56	A Non-inferiority Pilot Study Comparing the Clinical Efficacy and Safety of Generic Wide-spectrum Antibiotic Use in Septic Oncology Patients. Drug Research, 2015, 65, 635-639.	0.7	4
57	Prevalence of seven cardiovascular-related genetic polymorphisms in a Chilean mestizo healthy population. Acta Cardiologica, 2015, 70, 528-35.	0.3	2
58	Can pharmacogenetics explain efficacy and safety of cisplatin pharmacotherapy?. Frontiers in Genetics, 2014, 5, 391.	1.1	26
59	Impact of CYP1A1, GSTM1, and GSTT1 polymorphisms in overall and specific prostate cancer survival. Urologic Oncology: Seminars and Original Investigations, 2014, 32, 280-290.	0.8	7
60	Perception of the Usefulness of Drug/Gene Pairs and Barriers for Pharmacogenomics in Latin America. Current Drug Metabolism, 2014, 15, 202-208.	0.7	31
61	Multicriteria Analysis to Support Environmental Management Decision: Selecting an Indoor Heating Alternatives at the South of Chile. , 2014, , .		0
62	Frecuencia de los polimorfismos CYP1A1*2A y deleción del gen GSTM1 en pacientes con carcinoma de células escamosas de laringe en relación al hábito tabáquico: Estudio piloto en Chile. Revista De OtorrinolaringologÃa Y CirugÃa De Cabeza Y Cuello, 2013, 73, 7-16.	0.0	3
63	Bioequivalence of Acenocoumarol in Chilean Volunteers: an Open, Randomized, Double-Blind, Single-Dose, 2-Period, and 2-Sequence Crossover Study for 2 Oral Formulations. Arzneimittelforschung, 2012, 62, 395-399.	0.5	5
64	Frequencies of 23 Functionally Significant Variant Alleles Related with Metabolism of Antineoplastic Drugs in the Chilean Population: Comparison with Caucasian and Asian Populations. Frontiers in Genetics, 2012, 3, 229.	1.1	61
65	Influencia de polimorfismos genéticos de CYP3A4/5 en la farmacocinética de levonorgestrel: estudio piloto. Biomedica, 2012, 32, .	0.3	13
66	Determinación del polimorfismo de CYP2C9*2 y su relación con la farmacocinética de acenocumarol en voluntarios sanos. Revista Chilena De CardiologÃa, 2011, 30, 218-224.	0.0	2
67	Oral cancer susceptibility associated with the CYP1A1 and GSTM1 genotypes in Chilean individuals. Oncology Letters, 2010, 1, 549-553.	0.8	19
68	A comparative bioavailability study of two formulations of pregabalin in healthy Chilean volunteers. Therapeutic Advances in Chronic Disease, 2010, 1, 141-148.	1.1	7
69	Polymorphism of <i>Glutathione S-Transferase </i> ( <i>GST </i> ) Variants and Its Effect on Distribution of Urinary Arsenic Species in People Exposed to Low Inorganic Arsenic in Tap Water: An Exploratory Study. Archives of Environmental and Occupational Health, 2010, 65, 140-147.	0.7	15
70	Relative bioavailability study with two oral formulations of topiramate using a validated UPLC-MS/MS method. International Journal of Clinical Pharmacology and Therapeutics, 2010, 48, 342-348.	0.3	4
71	Association Between p53 codon 72 Genetic Polymorphism and Tobacco Use and Lung Cancer Risk. Lung, 2009, 187, 110-115.	1.4	17
72	Study of Cytochrome P450 2E1 and its allele Variants in Liver Injury of Nondiabetic, Nonalcoholic Steatohepatitis Obese Women. Biological Research, 2008, 41, .	1.5	33

#	Article	IF	CITATIONS
73	Study of cytochrome P450 2E1 and its allele variants in liver injury of nondiabetic, nonalcoholic steatohepatitis obese women. Biological Research, 2008, 41, 81-92.	1.5	17
74	Joint effect among p53, CYP1A1, GSTM1 polymorphism combinations and smoking on prostate cancer risk: an exploratory genotype-environment interaction study. Asian Journal of Andrology, 2006, 8, 349-355.	0.8	57
75	Relationship among metabolizing genes, smoking and alcohol used as modifier factors on prostate cancer risk: Exploring some gene?gene and gene?environment interactions. European Journal of Epidemiology, 2005, 20, 79-88.	2.5	38
76	Oxidative stress-related parameters in the liver of non-alcoholic fatty liver disease patients. Clinical Science, 2004, 106, 261-268.	1.8	426
77	Effects of g-hexachlorocyclohexane and L-3,3',5- triiodothyronine on rat liver cytochrome P4502E1-dependent activity and content in relation to microsomal superoxide radical generation. Biological Research, 2003, 36, 359-65.	1.5	17
78	CYP1A1, CYP2E1 and GSTM1 genetic polymorphisms. The effect of single and combined genotypes on lung cancer susceptibility in Chilean people. Cancer Letters, 2001, 174, 35-44.	3.2	121
79	Hepatic enzyme induction and mutagenicity of airborne particulate matter from Santiago, Chile in the nourished and malnourished rat. Xenobiotica, 1997, 27, 527-536.	0.5	4
80	Induction of rat hepatic P4501A1 by organic extracts from airborne particulate matter in Santiago, Chile. Xenobiotica, 1995, 25, 81-89.	0.5	18